• BSE
  • NSE
    • {{d.cmpname}}
    • {{d.price}}
    • ({{d.PerChg}}%)
Equity | News | Hot Pursuit
Hot Pursuit
Unichem Labs gains after ANDA approvals
(12:30, 13 Aug 2019)

Unichem Laboratories announced today, 13 August 2019, that it received Abbreviated New Drug Application (ANDA) approval from US Food and Drug Administration (USFDA) for Unichem's Tramadol Hydrochloride tablets USP, 50 mg, a generic version of Ultram tablets of Janssen Pharmaceuticals, Inc. The drug is indicated to adults for the management of pain, severe enough to require an opioid analgesic and for which alternative treatments are inadequate. The product will be commercialized from Unichem's Ghaziabad plant.

In a separate announcement yesterday, the company said it received ANDA approval from USFDA for Chlorthalidone tablets USP, 25 mg and 50 mg, a generic version of Hygroton tablets of Sanofi Aventis US, LLC. The drug is indicated for the management of hypertension either as the sole therapeutic agent or to enhance the effect of other anti-hypertensive drugs in the more severe forms of hypertension. It is also indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. It also treats edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. The product will be commercialized from Unichem's Ghaziabad plant.

Unichem Laboratories' reported a consolidated net loss of Rs 6.19 crore in Q1 June 2019 compared with net loss of Rs 20.46 crore in Q1 June 2018. Its net sales surged 23.5% to Rs 297.74 crore in Q1 June 2019 over Q1 June 2018.

Unichem Laboratories is an international, integrated and specialty pharmaceutical company.

Powered by Capital Market - Live News

DB (International) Stock Brokers Limited: SEBI Reg. No.-INZ000179035 / CDSL : IN-DP-CDSL-266-2004 MCX-SX:INE 260643233/21500(CD)
Daga Commodities Private Limited: SEBI Reg. No. INZ000028833
Investor Grievances Email ID: compliance@dbonline.in & investors@dbonline.in
Copyright © 2016 All rights Reserved DB (International) Stock Brokers Ltd.     Designed, Developed and content powered by C-MOTS Infotech( ISO 9001:2015 certified )
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."         "Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day......................issued in the interest of investors."          "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Attention Investors ::
subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries